1	Two	CD	3	num
2	Japanese	JJ	3	amod
3	scientists	NNS	4	nsubj
4	said	VBD	0	root
5	they	PRP	6	nsubj
6	discovered	VBD	4	ccomp
7	an	DT	8	det
8	antibody	NN	6	dobj
9	that	IN	16	nsubj
10	,	,	16	punct
11	in	IN	16	prep
12	laboratory	NN	14	nn
13	test-tube	NN	14	nn
14	experiments	NNS	11	pobj
15	,	,	16	punct
16	kills	VBZ	8	rcmod
17	AIDS-infected	JJ	18	amod
18	cells	NNS	16	dobj
19	while	IN	20	mark
20	preserving	VBG	16	advcl
21	healthy	JJ	22	amod
22	cells	NNS	20	dobj
23	.	.	4	punct

1	If	IN	5	mark
2	further	JJ	3	amod
3	experiments	NNS	5	nsubj
4	are	VBP	5	cop
5	successful	JJ	10	advcl
6	,	,	10	punct
7	the	DT	8	det
8	work	NN	10	nsubj
9	would	MD	10	aux
10	represent	VB	0	root
11	a	DT	13	det
12	major	JJ	13	amod
13	advance	NN	10	dobj
14	in	IN	13	prep
15	research	NN	14	pobj
16	on	IN	15	prep
17	acquired	VBN	20	amod
18	immune	JJ	19	amod
19	deficiency	NN	20	nn
20	syndrome	NN	16	pobj
21	.	.	10	punct

1	The	DT	3	det
2	drug	NN	3	nn
3	AZT	NNP	13	nsubj
4	,	,	3	punct
5	the	DT	7	det
6	only	JJ	7	amod
7	treatment	NN	3	appos
8	currently	RB	7	rcmod
9	on	IN	8	dep
10	the	DT	11	det
11	market	NN	9	pobj
12	,	,	3	punct
13	claims	VBZ	0	root
14	only	RB	16	advmod
15	to	TO	16	aux
16	help	VB	13	ccomp
17	stop	VB	16	ccomp
18	the	DT	19	det
19	spread	NN	17	dobj
20	of	IN	19	prep
21	AIDS	NNP	20	pobj
22	,	,	16	punct
23	not	RB	16	neg
24	to	TO	25	aux
25	cure	VB	16	dep
26	it	PRP	25	dobj
27	.	.	13	punct

1	But	CC	22	cc
2	several	JJ	3	amod
3	analysts	NNS	22	nsubj
4	and	CC	3	cc
5	Japanese	JJ	6	amod
6	scientists	NNS	3	conj
7	familiar	JJ	3	amod
8	with	IN	7	prep
9	the	DT	10	det
10	study	NN	8	pobj
11	,	,	10	punct
12	which	WDT	14	nsubjpass
13	was	VBD	14	auxpass
14	announced	VBN	10	rcmod
15	at	IN	14	prep
16	a	DT	17	det
17	conference	NN	15	pobj
18	in	IN	17	prep
19	Nagoya	NNP	18	pobj
20	yesterday	NN	14	tmod
21	,	,	10	punct
22	expressed	VBD	0	root
23	skepticism	NN	22	dobj
24	over	IN	22	prep
25	the	DT	26	det
26	significance	NN	24	pobj
27	of	IN	26	prep
28	the	DT	29	det
29	results	NNS	27	pobj
30	.	.	22	punct

1	And	CC	5	cc
2	the	DT	3	det
3	researchers	NNS	5	nsubj
4	themselves	PRP	3	dep
5	acknowledged	VBD	0	root
6	they	PRP	9	nsubj
7	still	RB	9	advmod
8	must	MD	9	aux
9	do	VB	5	ccomp
10	much	RB	11	advmod
11	more	JJR	12	amod
12	work	NN	9	dobj
13	before	IN	16	mark
14	they	PRP	16	nsubj
15	can	MD	16	aux
16	say	VB	9	advcl
17	whether	IN	22	complm
18	the	DT	19	det
19	treatment	NN	22	nsubj
20	would	MD	22	aux
21	actually	RB	22	advmod
22	cure	VB	16	ccomp
23	humans	NNS	22	dobj
24	.	.	5	punct

1	Shin	NNP	2	nn
2	Yonehara	NNP	16	nsubj
3	,	,	2	punct
4	a	DT	6	det
5	research	NN	6	nn
6	scientist	NN	2	appos
7	at	IN	6	prep
8	the	DT	11	det
9	Tokyo	NNP	11	nn
10	Metropolitan	NNP	11	nn
11	Institute	NNP	7	pobj
12	of	IN	11	prep
13	Medical	NNP	14	nn
14	Science	NNP	12	pobj
15	,	,	2	punct
16	said	VBD	0	root
17	the	DT	18	det
18	antibody	NN	21	nsubj
19	he	PRP	20	nsubj
20	discovered	VBD	18	rcmod
21	works	VBZ	16	ccomp
22	by	IN	21	prep
23	recognizing	VBG	22	pcomp
24	an	DT	25	det
25	antigen	NN	23	dobj
26	called	VBN	25	partmod
27	a	DT	28	det
28	Fas-antigen	NN	26	dep
29	,	,	25	punct
30	which	WDT	32	nsubj
31	is	VBZ	32	cop
32	characteristic	JJ	25	rcmod
33	of	IN	32	prep
34	an	DT	36	det
35	infected	JJ	36	amod
36	cell	NN	33	pobj
37	.	.	16	punct

1	The	DT	2	det
2	antibody	NN	4	nsubj
3	then	RB	4	advmod
4	kills	VBZ	0	root
5	the	DT	6	det
6	cell	NN	4	dobj
7	.	.	4	punct

1	Dr.	NNP	2	nn
2	Yonehara	NNP	13	nsubj
3	and	CC	2	cc
4	his	PRP$	5	poss
5	partner	NN	2	conj
6	,	,	5	punct
7	Nobuyuki	NNP	8	nn
8	Kobayashi	NNP	5	appos
9	of	IN	8	prep
10	Yamaguchi	NNP	11	nn
11	University	NNP	9	pobj
12	,	,	5	punct
13	said	VBD	0	root
14	their	PRP$	15	poss
15	experiments	NNS	16	nsubj
16	showed	VBD	13	ccomp
17	that	IN	20	complm
18	the	DT	19	det
19	antibody	NN	20	nsubj
20	wiped	VBD	16	ccomp
21	out	RP	20	prt
22	an	DT	23	det
23	average	NN	20	dobj
24	of	IN	23	prep
25	60	CD	26	num
26	%	NN	24	pobj
27	of	IN	26	prep
28	AIDS-infected	JJ	29	amod
29	cells	NNS	27	pobj
30	within	IN	20	prep
31	three	CD	32	num
32	days	NNS	30	pobj
33	.	.	13	punct

1	In	IN	8	prep
2	some	DT	1	pobj
3	of	IN	2	prep
4	the	DT	5	det
5	experiments	NNS	3	pobj
6	,	,	8	punct
7	it	PRP	8	nsubj
8	killed	VBD	17	ccomp
9	almost	RB	10	quantmod
10	all	PDT	13	num
11	the	DT	13	det
12	infected	JJ	13	amod
13	cells	NNS	8	dobj
14	,	,	17	punct
15	the	DT	16	det
16	researchers	NNS	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct

1	Meanwhile	RB	12	advmod
2	,	,	12	punct
3	fewer	JJR	4	mwe
4	than	IN	5	quantmod
5	10	CD	6	num
6	%	NN	12	nsubjpass
7	of	IN	6	prep
8	the	DT	10	det
9	healthy	JJ	10	amod
10	cells	NNS	7	pobj
11	were	VBD	12	auxpass
12	killed	VBN	0	root
13	.	.	12	punct

1	The	DT	2	det
2	two	CD	3	nsubj
3	said	VBD	0	root
4	they	PRP	7	nsubj
5	must	MD	7	aux
6	still	RB	7	advmod
7	do	VB	3	ccomp
8	more	JJR	10	amod
9	laboratory	NN	10	nn
10	tests	NNS	7	dobj
11	,	,	7	punct
12	then	RB	7	advmod
13	experiment	NN	7	dep
14	on	IN	13	prep
15	animals	NNS	14	pobj
16	.	.	3	punct

1	They	PRP	2	nsubj
2	said	VBD	0	root
3	they	PRP	4	nsubj
4	hoped	VBD	2	ccomp
5	to	TO	6	aux
6	conduct	VB	4	xcomp
7	tests	NNS	6	dobj
8	on	IN	6	prep
9	human	JJ	10	amod
10	patients	NNS	8	pobj
11	in	IN	10	prep
12	the	DT	13	det
13	U.S.	NNP	11	pobj
14	by	IN	6	prep
15	late	JJ	17	amod
16	next	JJ	17	amod
17	year	NN	14	pobj
18	.	.	2	punct

1	Japan	NNP	4	nsubj
2	does	VBZ	4	aux
3	n't	RB	4	neg
4	have	VB	17	ccomp
5	enough	JJ	7	amod
6	AIDS	NNP	7	nn
7	patients	NNS	4	dobj
8	to	TO	9	aux
9	do	VB	7	infmod
10	significant	JJ	11	amod
11	experimentation	NN	9	dobj
12	in	IN	9	prep
13	that	DT	14	det
14	country	NN	12	pobj
15	,	,	17	punct
16	they	PRP	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct

1	The	DT	2	det
2	announcement	NN	3	nsubj
3	got	VBD	0	root
4	wide	JJ	5	amod
5	exposure	NN	3	dobj
6	in	IN	3	prep
7	the	DT	9	det
8	Japanese	JJ	9	amod
9	media	NNS	6	pobj
10	,	,	3	punct
11	and	CC	3	cc
12	even	RB	13	advmod
13	moved	VBD	3	conj
14	some	DT	16	det
15	pharmaceutical	JJ	16	amod
16	stocks	NNS	13	dobj
17	yesterday	NN	13	tmod
18	.	.	3	punct

1	But	CC	26	cc
2	Takashi	NNP	3	nn
3	Kitamura	NNP	26	nsubj
4	,	,	3	punct
5	director	NN	3	appos
6	of	IN	5	prep
7	the	DT	9	det
8	biology	NN	9	nn
9	department	NN	6	pobj
10	at	IN	9	prep
11	Japan	NNP	14	poss
12	's	POS	11	possessive
13	National	NNP	14	nn
14	Institute	NNP	10	pobj
15	of	IN	14	prep
16	Health	NNP	15	pobj
17	and	CC	5	cc
18	secretary	NN	5	conj
19	of	IN	18	prep
20	the	DT	21	det
21	government	NN	24	poss
22	's	POS	21	possessive
23	AIDS-research	JJ	24	amod
24	center	NN	19	pobj
25	,	,	3	punct
26	said	VBD	0	root
27	,	,	26	punct
28	``	``	26	punct
29	I	PRP	33	nsubj
30	'm	VBP	33	cop
31	not	RB	33	neg
32	so	RB	33	advmod
33	optimistic	JJ	26	ccomp
34	of	IN	33	prep
35	its	PRP$	37	poss
36	future	JJ	37	amod
37	use	NN	34	pobj
38	in	IN	37	prep
39	therapeutic	JJ	40	amod
40	methods	NNS	38	pobj
41	.	.	26	punct
42	''	''	26	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	some	DT	5	det
4	infected	JJ	5	amod
5	cells	NNS	8	nsubj
6	may	MD	8	aux
7	not	RB	8	neg
8	have	VB	2	ccomp
9	the	DT	11	det
10	relevant	JJ	11	amod
11	antigen	NN	8	dobj
12	and	CC	8	cc
13	so	RB	17	advmod
14	would	MD	17	aux
15	n't	RB	17	neg
16	be	VB	17	auxpass
17	killed	VBN	8	conj
18	even	RB	19	advmod
19	after	IN	17	prep
20	exposure	NN	19	pobj
21	to	TO	20	prep
22	the	DT	23	det
23	antibody	NN	21	pobj
24	.	.	2	punct

1	``	``	11	punct
2	The	DT	3	det
3	results	NNS	4	nsubj
4	seem	VBP	11	ccomp
5	to	TO	8	aux
6	be	VB	8	cop
7	very	RB	8	advmod
8	premature	JJ	4	xcomp
9	,	,	11	punct
10	''	''	11	punct
11	said	VBD	0	root
12	Mitsuru	NNP	13	nn
13	Miyata	NNP	11	nsubj
14	,	,	13	punct
15	editor	NN	13	appos
16	of	IN	15	prep
17	Nikkei	NNP	18	nn
18	Biotechnology	NNP	16	pobj
19	,	,	18	punct
20	a	DT	24	det
21	leading	VBG	24	amod
22	Japanese	JJ	24	amod
23	industry	NN	24	nn
24	newsletter	NN	18	appos
25	.	.	11	punct

1	Dr.	NNP	2	nn
2	Kobayashi	NNP	3	nsubj
3	responded	VBD	0	root
4	that	IN	6	complm
5	he	PRP	6	nsubj
6	thought	VBD	3	ccomp
7	the	DT	8	det
8	antibody	NN	11	nsubj
9	could	MD	11	aux
10	potentially	RB	11	advmod
11	kill	VB	6	ccomp
12	all	DT	14	det
13	infected	JJ	14	amod
14	cells	NNS	11	dobj
15	.	.	3	punct

1	But	CC	6	cc
2	he	PRP	6	nsubj
3	and	CC	2	cc
4	Dr.	NNP	5	nn
5	Yonehara	NNP	2	conj
6	said	VBD	0	root
7	there	EX	8	expl
8	were	VBD	6	ccomp
9	still	RB	8	advmod
10	several	JJ	11	amod
11	uncertainties	NNS	8	nsubj
12	,	,	11	punct
13	particularly	RB	11	rcmod
14	regarding	VBG	13	dep
15	possible	JJ	17	amod
16	side	NN	17	nn
17	effects	NNS	14	pobj
18	.	.	6	punct

1	``	``	23	punct
2	Our	PRP$	3	poss
3	antibody	NN	5	nsubj
4	specifically	RB	5	advmod
5	killed	VBD	23	ccomp
6	infected	JJ	7	amod
7	cells	NNS	5	dobj
8	at	IN	5	prep
9	a	DT	12	det
10	very	RB	11	advmod
11	low	JJ	12	amod
12	dose	NN	8	pobj
13	,	,	5	punct
14	but	CC	5	cc
15	it	PRP	18	nsubj
16	can	MD	18	aux
17	also	RB	18	advmod
18	kill	VB	5	conj
19	other	JJ	20	amod
20	cells	NNS	18	dobj
21	,	,	23	punct
22	''	''	23	punct
23	said	VBD	0	root
24	Dr.	NNP	25	nn
25	Yonehara	NNP	23	nsubj
26	.	.	23	punct

1	``	``	5	punct
2	We	PRP	5	nsubj
3	do	VBP	5	aux
4	n't	RB	5	neg
5	know	VB	0	root
6	the	DT	7	det
7	effect	NN	5	dobj
8	of	IN	7	prep
9	our	PRP$	10	poss
10	antibody	NN	8	pobj
11	on	IN	7	prep
12	the	DT	14	det
13	human	JJ	14	amod
14	body	NN	11	pobj
15	.	.	5	punct
16	''	''	5	punct

1	AIDS	NNP	4	nsubjpass
2	is	VBZ	4	auxpass
3	n't	RB	4	neg
4	considered	VBN	0	root
5	a	DT	7	det
6	widespread	JJ	7	amod
7	problem	NN	4	xcomp
8	in	IN	7	prep
9	Japan	NNP	8	pobj
10	--	:	4	punct
11	the	DT	12	det
12	government	NN	13	nsubj
13	reports	VBZ	4	conj
14	about	IN	15	quantmod
15	1,000	CD	17	num
16	known	VBN	17	amod
17	carriers	NNS	13	dobj
18	of	IN	17	prep
19	the	DT	20	det
20	virus	NN	18	pobj
21	--	:	4	punct
22	but	CC	4	cc
23	many	JJ	24	amod
24	companies	NNS	26	nsubj
25	have	VBP	26	aux
26	poured	VBN	4	conj
27	substantial	JJ	28	amod
28	resources	NNS	26	dobj
29	into	IN	26	prep
30	research	NN	29	pobj
31	in	IN	26	prep
32	recent	JJ	33	amod
33	years	NNS	31	pobj
34	,	,	26	punct
35	hoping	VBG	26	partmod
36	to	TO	37	aux
37	cash	VB	35	xcomp
38	in	RP	37	prt
39	on	IN	37	prep
40	a	DT	42	det
41	possible	JJ	42	amod
42	cure	NN	39	pobj
43	.	.	4	punct

1	Dr.	NNP	2	nn
2	Kitamura	NNP	3	nsubj
3	said	VBD	0	root
4	about	IN	5	quantmod
5	35	CD	6	num
6	projects	NNS	7	nsubj
7	are	VBP	3	ccomp
8	currently	RB	7	advmod
9	under	IN	7	prep
10	way	NN	9	pobj
11	in	IN	7	prep
12	Japan	NNP	11	pobj
13	,	,	7	punct
14	and	CC	7	cc
15	that	IN	23	complm
16	Japanese	JJ	17	amod
17	researchers	NNS	23	nsubj
18	in	IN	17	prep
19	the	DT	21	det
20	past	JJ	21	amod
21	year	NN	18	pobj
22	have	VBP	23	aux
23	made	VBN	7	conj
24	available	JJ	23	acomp
25	three	CD	27	num
26	possible	JJ	27	amod
27	cures	NNS	24	dep
28	to	TO	24	dep
29	American	JJ	30	amod
30	researchers	NNS	28	pobj
31	for	IN	24	dep
32	clinical	JJ	33	amod
33	tests	NNS	31	pobj
34	.	.	3	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	that	IN	21	complm
4	when	WRB	10	advmod
5	scientists	NNS	10	nsubj
6	from	IN	5	prep
7	the	DT	9	det
8	two	CD	9	num
9	countries	NNS	6	pobj
10	meet	VBP	21	advcl
11	again	RB	10	advmod
12	in	IN	10	prep
13	January	NNP	12	pobj
14	in	IN	10	prep
15	New	NNP	16	nn
16	Orleans	NNP	14	pobj
17	,	,	21	punct
18	the	DT	19	det
19	Japanese	NNP	21	nsubj
20	will	MD	21	aux
21	present	VB	2	ccomp
22	at	IN	24	quantmod
23	least	JJS	22	mwe
24	three	CD	26	dep
25	more	JJR	24	dep
26	drugs	NNS	21	dobj
27	for	IN	21	prep
28	human	JJ	29	amod
29	testing	NN	27	pobj
30	.	.	2	punct

1	AZT	NNP	8	nsubj
2	is	VBZ	8	cop
3	the	DT	4	det
4	world	NN	8	poss
5	's	POS	4	possessive
6	only	JJ	8	amod
7	prescription	NN	8	nn
8	medicine	NN	0	root
9	approved	VBN	8	partmod
10	for	IN	9	prep
11	treating	VBG	10	pcomp
12	the	DT	13	det
13	disease	NN	11	dobj
14	.	.	8	punct

1	Wellcome	NNP	2	nn
2	PLC	NNP	10	nsubj
3	,	,	2	punct
4	a	DT	8	det
5	major	JJ	8	amod
6	British	JJ	8	amod
7	pharmaceutical	NN	8	nn
8	maker	NN	2	appos
9	,	,	2	punct
10	sells	VBZ	0	root
11	the	DT	12	det
12	drug	NN	10	dobj
13	under	IN	10	prep
14	the	DT	15	det
15	name	NN	13	pobj
16	Retrovir	NNP	15	dep
17	.	.	10	punct

1	A	DT	3	det
2	Wellcome	NNP	3	nn
3	spokesman	NN	4	nsubj
4	declined	VBD	0	root
5	to	TO	6	aux
6	comment	VB	4	xcomp
7	on	IN	6	prep
8	the	DT	9	det
9	discovery	NN	7	pobj
10	of	IN	9	prep
11	the	DT	12	det
12	antibody	NN	10	pobj
13	in	IN	9	prep
14	Japan	NNP	13	pobj
15	.	.	4	punct

1	But	CC	15	cc
2	Andrew	NNP	3	nn
3	Porter	NNP	15	nsubj
4	,	,	3	punct
5	a	DT	7	det
6	drug-industry	NN	7	nn
7	analyst	NN	3	appos
8	at	IN	7	prep
9	Nikko	NNP	10	nn
10	Securities	NNPS	11	nn
11	Co.	NNP	8	pobj
12	in	IN	11	prep
13	London	NNP	12	pobj
14	,	,	3	punct
15	said	VBD	0	root
16	if	IN	19	mark
17	the	DT	18	det
18	product	NN	19	nsubj
19	were	VBD	26	advcl
20	to	TO	23	aux
21	be	VB	23	auxpass
22	successfully	RB	23	advmod
23	developed	VBN	19	xcomp
24	it	PRP	26	nsubj
25	would	MD	26	aux
26	represent	VB	15	ccomp
27	``	``	26	punct
28	a	DT	30	det
29	potential	JJ	30	amod
30	threat	NN	26	dobj
31	to	TO	30	prep
32	the	DT	34	det
33	long-term	JJ	34	amod
34	viability	NN	31	pobj
35	of	IN	34	prep
36	Retrovir	NNP	35	pobj
37	.	.	15	punct


